Strategy. From people who have held the role.
12+
Decades
Preclinical to LCM
Operator Led
The thesis.
Most strategy fails the same way: a confident slide presentation by people who have never had to make it work. An unrealistic peak-sales figure. A pricing strategy no payer would allow. A sales approach no rep would carry. A launch plan that assumes the competitor will stand still. A portfolio call made on the team's gut, not the market's reality. Beacon was built by operators to close that gap — to bring the judgment that only comes from having owned the brand, the launch, and the P&L, and to back it with bottom-up rigor and the voice of the people who decide whether a strategy wins or loses.
Kevin Rooney, Founder & President
Kevin Rooney founded Beacon Consulting Group on a simple conviction: biopharma's biggest decisions deserve more than a market report — they deserve a practitioner's judgment. Over a career spanning decades, he has partnered with pharmaceutical and biotech leadership teams on the questions that move enterprise value: which assets to prioritize, how to position and launch them, and what a program is truly worth in a deal. His work guides companies from preclinical stage through lifecycle management, and crosses all major therapeutic areas. He has also held C-level roles in Commercial and Corporate Strategy with multiple biotech companies. His approach blends deep quantitative rigor — market sizing, share forecasting, and financial modeling — with the strategic instinct to know which question actually matters. Clients rely on Beacon not for a deck, but for a clear point of view they can act on.
